The 379% return over the last year is very disappointing, yes. Barely beats the S&P, right?
Also, since you don't like factual positive info (such as the unprecedented Alzheimer's trial data released on Nov 9, which by the way came after the up listing), I'm curious what non-factual positive info you'd like to see. Maybe you want Missling to announce that AF took a dose of 2-73 and turned into a unicorn?
Maybe that would improve on our paltry 379% return over the last year?
Thanks, I will! Glad to see you still posting here, always one of the best.
Considering that a "definitive agreement to acquire" is already in place, it would only be news if the deal somehow fell apart.
You mean besides the Allergan CEO feeling the need to get defensive about 2-73 after spending $3.3B on an inferior semi-clone of 2-73 whose entire company was deemed worth less than 1/10 that amount before the release of the 2-73 data this year? Yeah, I'm sure BP's not interested, not in the slightest.
When data unprecedented in prior Alzheimer's trials comes out, shorts say Oh it must be the mother of all placebo effects, or maybe it's the coffee. They have very strong coffee in Australia, you know.
Sure, people with Alzheimer's who haven't been able to play piano for three years re-learn how to do it all the time. I think it's actually one of the major symptoms of late-stage Alzheimer's. After all, in the past we've seen dozens of Alzheimer's patients regain complex abilities like playing piano and painting and sustain them eight months after treatment, haven't we, despite the fact that in Alzheimer's trials the placebo effect is not seen beyond 12 weeks? Haven't we? I just can't seem to find the citations right now....
Anavex bought the 2-73 basic-composition patent from Vamvakides back in 2007. The patent adxs228 cites is an additional 2-73 patent for a particular application (I believe cancer-related, but I'm going from memory on that).
I disagree that we need the Plus patent. We have the 2-73 patent and that is enough to protect the company's IP. The Plus patent would just be gravy.
Can you cite an instance of a Semarnat decision going to the applicant first? I see no evidence of that. And even if it did go to the applicant first, does it really matter? The decision is clearly material and would need to be announced by Odyssey right away even if it were delivered privately first. Given the Fishery Cooperatives' support, it is obvious the decision will be favorable to the applicant.
No, you misunderstand me. They have not told anyone anything. THEY (the ECC) have received the decision, and no one else. I am sure they will announce that decision sometime this week, and I do not believe the applicant will find out before anyone else, but at the same time.
No, I read it in Spanish, both the article and the Semarnat website, because I understand Spanish. Then I translated a little of it here for people who do not understand Spanish.
I have been invested in Odyssey for about five years, indeed no more than I can afford to lose, and I currently break even at roughly $13-14. I expect the imminent Don Diego approval to carry the share price well beyond that point.
Regardless, even if I am wrong about the ECC, the note on the Semarnat website says the decision has been received by the ECC, not that the ECC has contacted either Odyssey or the Mexican people (via general announcement obviously).
Their name tells you they contact citizens (i.e. the Mexican people), not applicants. It's clearly a PR division of Semarnat.
Since the ECC translates as the Office of Citizen Contact (or literally the Space of Citizen Contact), I would say that is the general PR arm of Semarnat that will announce the decision to the people of Mexico, not to Odyssey/Oceanica.